Central Middlesex Hospital, London NW10.
1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)
USE OF HIGH DOSE CIS-DICHLORODIAMMINE PLATINUM (II) (NSC—119875) FOLLOWING FAILURE ON PREVIOUS CHEMOTHERAPY FOR ADVANCED CARCINOMA OF THE OVARY†
Article first published online: 23 AUG 2005
DOI: 10.1111/j.1471-0528.1981.tb01196.x
Issue
1471-0528/asset/cover.gif?v=1&s=b4e1d96c46e18c61210d584b63c13ee375cf562b "BJOG: An International Journal of Obstetrics & Gynaecology")
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 88, Issue 12, pages 1192–1199, December 1981
Additional Information
How to Cite
Barker, G. H. and Wiltshaw, E. (1981), USE OF HIGH DOSE CIS-DICHLORODIAMMINE PLATINUM (II) (NSC—119875) FOLLOWING FAILURE ON PREVIOUS CHEMOTHERAPY FOR ADVANCED CARCINOMA OF THE OVARY. BJOG: An International Journal of Obstetrics & Gynaecology, 88: 1192–1199. doi: 10.1111/j.1471-0528.1981.tb01196.x
- †
Cis-dichlorodiammine platinum (II) CAS Reg. No. 15665–27–1 Cisplatin supplied by Cancer Therapy Evaluation Programme, Division of Cancer Treatment, National Cancer Institute, U.S.A.
Publication History
- Issue published online: 23 AUG 2005
- Article first published online: 23 AUG 2005
- Received May 5, 1981/Accepted August 14, 1981
- Abstract
- References
- Cited By
Summary
Cis-dichlorodiammine platinum II (cisplatin) in high dose was given to 40 patients with advanced carcinoma of the ovary, 31 had been previously treated with alkyl-ating agents or various chemotherapy regimens excluding cisplatin and 9 patients had tumours resistant to low dose cisplatin regimens. The high dose regimen consisted of cisplatin given at 100 mg/m2 with 24 hours pre- and post-treatment hydration, at monthly intervals up to a maximum of 5 doses. Seventeen of the 31 patients (55%) showed a therapeutic response including 25% who had complete regression of tumour. The median duration of complete remissions was 10 months. Unfortunately, patients who had already been exposed to cisplatin at low doses (20 mg/m2) responded less well, only 2 out of 9 (22%). Even at this late stage of disease, seven patients showed a good enough response to undergo further surgery and of these three were macroscopically clear of tumour and in two patients multiple biopsy material failed to show residual tumour microscopically.